Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchUrsodeoxycholic acidUDCA (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV‐2 infection in children

Liu et al., Liver International, doi:10.1111/liv.15660
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case -2% Improvement Relative Risk Case (b) -4% UDCA for COVID-19  Liu et al.  Prophylaxis Does ursodeoxycholic acid reduce COVID-19 infections? Retrospective 226 patients in China No significant difference in cases c19early.org Liu et al., Liver Int., June 2023 FavorsUDCA Favorscontrol 0 0.5 1 1.5 2+
Retrospective 280 Chinese families with children previously seen in a liver clinic assessing whether ursodeoxycholic acid (UDCA) reduced SARS-CoV-2 infection risk. Among infected families, the study found no significant difference in confirmed or suspected SARS-CoV-2 infections between children taking UDCA (80.9%) and those not taking it (77.6%) (p=0.843).
risk of case, 2.1% higher, RR 1.02, p = 0.88, treatment 95 of 146 (65.1%), control 51 of 80 (63.7%), confirmed.
risk of case, 4.3% higher, RR 1.04, p = 0.61, treatment 118 of 146 (80.8%), control 62 of 80 (77.5%), confirmed + suspected.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Liu et al., 29 Jun 2023, retrospective, China, peer-reviewed, survey, 2 authors.
This PaperUDCAAll
{ 'indexed': {'date-parts': [[2023, 8, 15]], 'date-time': '2023-08-15T16:30:14Z', 'timestamp': 1692117014062}, 'reference-count': 12, 'publisher': 'Wiley', 'issue': '9', 'license': [ { 'start': { 'date-parts': [[2023, 6, 29]], 'date-time': '2023-06-29T00:00:00Z', 'timestamp': 1687996800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'funder': [ { 'DOI': '10.13039/501100001809', 'name': 'National Natural Science Foundation of China', 'doi-asserted-by': 'publisher', 'award': ['82201898']}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 9]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and ' 'Aims</jats:title><jats:p>A recent study suggested that administration of ursodeoxycholic acid ' '(UDCA) at dosages usually employed clinically may reduce rates of severe acute respiratory ' 'syndrome coronavirus 2 (SARS‐CoV‐2) infection. A recent surge of SARS‐CoV‐2 omicron infection ' 'in China allowed study of whether UDCA administration reduced susceptibility to SARS‐CoV‐2 ' 'infection in children with liver ' 'disease.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Through WeChat ' 'groups, a questionnaire was distributed to families (<jats:italic>n</jats:italic>\u2009=\u2009' '300) in which a child had been admitted to our liver service in the past 5\u2009years. Among ' 'the families/households in which someone was infected with SARS‐CoV‐2, the proportion in ' 'which a child taking UDCA was infected was compared with the proportion in which a child not ' 'taking UDCA was ' 'infected.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of the 300 ' 'questionnaire answers, 280 (93.3%) were valid. SARS‐CoV‐2 infection was confirmed in 226 ' 'families (80.7%): 146 children were taking UDCA (10‐20\u2009mg/kg/day) and 80 children were ' 'not taking UDCA. SARS‐CoV‐2 infection was confirmed in 95 children taking UDCA (65.1%) and in ' '51 children not taking UDCA (63.8%) (<jats:italic>p</jats:italic>\u2009=\u20090.843); ' 'SARS‐CoV‐2 infection was suspected in 23 children taking UDCA (15.8%) and in 11 children not ' 'taking UDCA (13.8%) (<jats:italic>p</jats:italic>\u2009=\u2009' '0.687).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>These ' 'results indicate that UDCA administration does not reduce susceptibility to SARS‐CoV‐2 ' 'infection in children with liver disease.</jats:p></jats:sec>', 'DOI': '10.1111/liv.15660', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 29]], 'date-time': '2023-06-29T07:35:17Z', 'timestamp': 1688024117000}, 'page': '1950-1954', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Ursodeoxycholic acid administration did not reduce susceptibility to <scp>SARS‐CoV</scp>‐2 ' 'infection in children', 'prefix': '10.1111', 'volume': '43', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-0858-2151', 'authenticated-orcid': False, 'given': 'Teng', 'family': 'Liu', 'sequence': 'first', 'affiliation': [ { 'name': "The Center for Pediatric Liver Diseases Children's Hospital of " 'Fudan University Shanghai China'}, { 'name': 'Department of Pediatrics Shanghai Medical College, Fudan ' 'University Shanghai China'}]}, { 'ORCID': 'http://orcid.org/0000-0003-0823-586X', 'authenticated-orcid': False, 'given': 'Jian‐She', 'family': 'Wang', 'sequence': 'additional', 'affiliation': [ { 'name': "The Center for Pediatric Liver Diseases Children's Hospital of " 'Fudan University Shanghai China'}, { 'name': 'Department of Pediatrics Shanghai Medical College, Fudan ' 'University Shanghai China'}]}], 'member': '311', 'published-online': {'date-parts': [[2023, 6, 29]]}, 'reference': [ {'key': 'e_1_2_14_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-021-04385-3'}, {'key': 'e_1_2_14_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41591-021-01310-z'}, {'key': 'e_1_2_14_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3762/bjoc.14.33'}, {'key': 'e_1_2_14_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-022-05594-0'}, { 'key': 'e_1_2_14_6_1', 'unstructured': 'YanL.https://www.ecns.cn/news/society/2022‐12‐28/detail‐ihciertf7993989.shtml. ' 'Accessed December 28 2022'}, {'key': 'e_1_2_14_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/hep.1840190629'}, {'key': 'e_1_2_14_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2005073'}, {'key': 'e_1_2_14_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41579-020-00459-7'}, {'key': 'e_1_2_14_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.it.2020.10.004'}, { 'key': 'e_1_2_14_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.biopha.2022.113021'}, { 'key': 'e_1_2_14_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/01.mpg.0000226386.79483.7b'}, { 'key': 'e_1_2_14_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.puhe.2021.12.003'}], 'container-title': 'Liver International', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15660', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 8, 12]], 'date-time': '2023-08-12T06:45:21Z', 'timestamp': 1691822721000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1111/liv.15660'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 6, 29]]}, 'references-count': 12, 'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2023, 9]]}}, 'alternative-id': ['10.1111/liv.15660'], 'URL': 'http://dx.doi.org/10.1111/liv.15660', 'relation': {}, 'ISSN': ['1478-3223', '1478-3231'], 'subject': ['Hepatology'], 'container-title-short': 'Liver International', 'published': {'date-parts': [[2023, 6, 29]]}, 'assertion': [ { 'value': '2023-01-12', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-06-15', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-06-29', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit